Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Campbell, Craig I ^a   Moorehead, Roger A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Breast cancer; Igf ir; Migration; Pdgfr; Resistance

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SOMATOMEDIN C RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL; UPREGULATION; ANIMAL; CELL MOTION; CELL SURVIVAL; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, IGF TYPE 1; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 80655139160     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-480     Document Type: Article

References (47)

1. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280. 10.1038/ncponc0509, 16683005.
2. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009, 30:51-74.
3. Arteaga C, Kitten K, Coronado E. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989, 84:1418-1423. 10.1172/JCI114315, 304004, 2553774.
4. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003, 63:8912-8921.
5. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000, 7:384-395. 10.1038/sj.cgt.7700126, 10766344.
6. Chernicky CL, Tan H, Yi L, Loret D, Ilan J. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Mol Pathol 2002, 55:102-109. 10.1136/mp.55.2.102, 1187158, 11950959.
7. Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, et al. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3 K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004, 23:5161-5174. 10.1038/sj.onc.1207659, 15122317.
8. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246. 10.1158/0008-5472.CAN-08-2755, 19074892.
9. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021. 10.1038/onc.2009.172, 19581933.
10. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia 2008, 13:471-483. 10.1007/s10911-008-9104-6, 2728362, 19023648.
11. Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Semin Oncol 2003, 30:125-132.
12. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26:1636-1644. 10.1038/sj.onc.1209955, 16953219.
13. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene 2008, 13:407-413.
14. Franks SE, Campbell CI, Barnett EF, Siwicky MD, Livingstone J, Cory S, et al. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics while IGF-IR independent mammary tumors express a claudin-low gene signature. Oncogene 2011,
15. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006, 81:1241-1257. 10.4065/81.9.1241, 16970222.
16. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004, 15:197-204. 10.1016/j.cytogfr.2004.03.007, 15207811.
17. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res C Embryo Today 2003, 69:272-285. 10.1002/bdrc.10030, 14745969.
18. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003, 36:49-59. 10.5483/BMBRep.2003.36.1.049, 12542975.
19. Bhardwaj B, Klassen J, Cossette N, Sterns E, Tuck A, Deeley R, et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996, 2:773-782.
20. Coltrera MD, Wang J, Porter PL, Gown AM. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 1995, 55:2703-2708.
21. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005, 7:R788-R795. 10.1186/bcr1304, 1242156, 16168125.
22. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006, 116:1561-1570. 10.1172/JCI24652, 1469776, 16741576.
23. Paulsson Y, Hammacher A, Heldin CH, Westermark B. Possible positive autocrine feedback in the prereplicative phase of human fibroblasts. Nature 1987, 328:715-717. 10.1038/328715a0, 3497351.
24. Jones RA, Campbell CI, Petrik JJ, Moorehead RA. Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor. Mol Cancer Res 2008, 6:819-828. 10.1158/1541-7786.MCR-07-2157, 18505926.
25. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene 2005,
26. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997, 411:77-82. 10.1016/S0014-5793(97)00669-8, 9247146.
27. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010, 70:7221-7231. 10.1158/0008-5472.CAN-10-0391, 20807811.
28. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105:8387-8392. 10.1073/pnas.0803383105, 2448846, 18550829.
29. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990, 85:916-920. 10.1172/JCI114519, 296510, 2155930.
30. Vassbotn FS, Ostman A, Siegbahn A, Holmsen H, Heldin CH. Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF alpha- and beta-receptor signals in cells expressing both receptor types. J Biol Chem 1992, 267:15635-15641.
31. Wennstrom S, Siegbahn A, Yokote K, Arvidsson AK, Heldin CH, Mori S, et al. Membrane ruffling and chemotaxis transduced by the PDGF beta-receptor require the binding site for phosphatidylinositol 3' kinase. Oncogene 1994, 9:651-660.
32. Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat 2011, 126:15-25. 10.1007/s10549-010-0883-2, 20379844.
33. Kang DW, Min D. Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFkappaB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett 2010, 294:125-133. 10.1016/j.canlet.2010.01.031, 20188462.
34. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004, 15:275-286. 10.1016/j.cytogfr.2004.03.002, 15207817.
35. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007, 97:247-274.
36. Faraone D, Aguzzi MS, Toietta G, Facchiano AM, Facchiano F, Magenta A, et al. Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia 2009, 11:732-742. 2713586, 19649203.
37. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007, 117:2114-2122. 10.1172/JCI31334, 1913488, 17641778.
38. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999, 16:201-216. 10.3109/08977199909002130, 10372961.
39. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001, 26:657-664. 10.1016/S0968-0004(01)01958-2, 11701324.
40. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
41. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006, 66:3963-3966. 10.1158/0008-5472.CAN-06-0743, 16618711.
42. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009, 69:161-170. 10.1158/0008-5472.CAN-08-0835, 19117999.
43. Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten EC, et al. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther 2011, 10:117-125. 10.1158/1535-7163.MCT-10-0438, 21220496.
44. Abraham J, Prajapati SI, Nishijo K, Schaffer BS, Taniguchi E, Kilcoyne A, et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther 2011, 10:697-707. 10.1158/1535-7163.MCT-10-0695, 21447712.
45. Campbell CI, Thompson DE, Siwicky MD, Moorehead RA. Murine mammary tumor cells with a claudin-low genotype. Cancer Cell International 2011, 11:28. 10.1186/1475-2867-11-28, 3170246, 21846397.
46. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
47. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.